Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...

CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% compared to the same quarter ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...

The new Phase 2 clinical trial protocol focuses on a specific patient population (advanced, recurrent, platinum-resistant ovarian cancer patients) with limited treatment options, highlighting the ...

Gibson, Dunn & Crutcher has filed multiple suits on behalf or organizations that provide legal services to immigrants, and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...